CytRx Corp (CYTR)

0.60
0.00 0.60
NASDAQ : Health Care
Prev Close 0.60
Open 0.58
Day Low/High 0.58 / 0.61
52 Wk Low/High 0.55 / 3.66
Volume 424.62K
Avg Volume 2.58M
Exchange NASDAQ
Shares Outstanding 96.94M
Market Cap 57.20M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Brower Piven Alerts Shareholders Of Upcoming Deadline In Class Action Lawsuit And Encourages Those With Losses From Investment In CytRx Corporation To Contact The Firm

Brower Piven Alerts Shareholders Of Upcoming Deadline In Class Action Lawsuit And Encourages Those With Losses From Investment In CytRx Corporation To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf...

CYTR SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving CytRx Corporation And A Lead Plaintiff Deadline Of September 23, 2016

CYTR SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving CytRx Corporation And A Lead Plaintiff Deadline Of September 23, 2016

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased CytRx Corporation (NASDAQ:CYTR) securities...

Federman & Sherwood Reminds Investors Of Imminent Lead Plaintiff Deadline In Securities Class Action Lawsuit Against CytRx Corporation

Federman & Sherwood Reminds Investors Of Imminent Lead Plaintiff Deadline In Securities Class Action Lawsuit Against CytRx Corporation

On July 25, 2016, a class action lawsuit was filed in the United States District Court for the Central District of California against CytRx Corporation (NASDAQ: CYTR).

STOCK NOTICE: Rosen Law Firm Reminds CytRx Corporation Investors Of Important Deadline In Class Action

STOCK NOTICE: Rosen Law Firm Reminds CytRx Corporation Investors Of Important Deadline In Class Action

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of CytRx Corporation securities (NASDAQ:CYTR) from November 18, 2014 through July 11, 2016, both...

Robbins Arroyo LLP: CytRx Corporation (CYTR) Misled Shareholders According To A Recently Filed Class Action

Robbins Arroyo LLP: CytRx Corporation (CYTR) Misled Shareholders According To A Recently Filed Class Action

Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against CytRx Corporation (NASDAQCM: CYTR) in the U.

INVESTOR ALERT: Brower Piven Notifies Shareholders Of Securities Class Action Lawsuit And Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In CytRx Corporation To Contact Brower Piven Before The Lead Plaintiff Deadline

INVESTOR ALERT: Brower Piven Notifies Shareholders Of Securities Class Action Lawsuit And Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In CytRx Corporation To Contact Brower Piven Before The Lead Plaintiff Deadline

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf...

CytRx Corporation Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

CytRx Corporation Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit...

CytRx (CYTR) Strong On High Relative Volume Today

CytRx (CYTR) Strong On High Relative Volume Today

Trade-Ideas LLC identified CytRx (CYTR) as a strong on high relative volume candidate

These 5 Stocks Are Poised for Breakouts

These 5 Stocks Are Poised for Breakouts

Here's a technical look at how to trade five stocks that are ready to break out and trade higher from current levels.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against CytRx Corporation - CYTR

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against CytRx Corporation - CYTR

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of CytRx Corporation securities (NASDAQ: CYTR) from November 18, 2014 through July 11, 2016, both...

Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of CytRx Corporation Investors And Encourages Investors To Contact The Firm

Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of CytRx Corporation Investors And Encourages Investors To Contact The Firm

Glancy Prongay & Murray LLP ("GPM") announces that it has filed a class action lawsuit in the United States District Court for the Central District of California on behalf of investors who purchased CytRx...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of CytRx Corporation

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of CytRx Corporation

Levi & Korsinsky announces it has commenced an investigation of CytRx Corporation (NASDAQ:CYTR) ("CytRx") concerning possible violations of federal securities laws by the Company and/or certain of its officers and...

Interesting CYTR Put And Call Options For March 2017

Interesting CYTR Put And Call Options For March 2017

Investors in CytRx Corp saw new options become available today, for the March 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

SHAREHOLDER NOTICE: Khang & Khang LLP Announces An Investigation Of CytRx Corporation And Reminds Investors With Losses To Contact The Firm

SHAREHOLDER NOTICE: Khang & Khang LLP Announces An Investigation Of CytRx Corporation And Reminds Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces that it is investigating claims against CytRx Corporation ("CytRx" or the "Company") (Nasdaq: CYTR) concerning possible violations of federal securities laws.

Trade-Ideas: CytRx (CYTR) Is Today's Weak On High Relative Volume Stock

Trade-Ideas: CytRx (CYTR) Is Today's Weak On High Relative Volume Stock

Trade-Ideas LLC identified CytRx (CYTR) as a weak on high relative volume candidate

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of CytRx Corporation

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of CytRx Corporation

Levi & Korsinsky announces it has commenced an investigation of CytRx Corporation (NASDAQ: CYTR) ("CytRx") concerning possible violations of federal securities laws by the Company and/or certain of its officers and...

CytRx Sarcoma Drug Flops in Late-Stage Clinical Trial

CytRx Sarcoma Drug Flops in Late-Stage Clinical Trial

The aldoxorubicin sarcoma study failure leaves CytRx with a depleted pipeline and 40 cents per share in cash.

CytRx Presents Updated Aldoxorubicin Clinical Trial Results At The 2016 American Society Of Clinical Oncology Annual Meeting

CytRx Presents Updated Aldoxorubicin Clinical Trial Results At The 2016 American Society Of Clinical Oncology Annual Meeting

Aldoxorubicin Continues to Demonstrate Safety and Anti-tumor Activity in Multiple Cancer Types